
The trial involves up to 26 trial visits over the course of about 76 weeks. Participants will be randomly assigned to receive either the study drug or a placebo (a substance that looks like the study drug but contains no ingredients), both given as intramuscular (in the muscle) injections.
Participants who complete the trial through Week 24 may be eligible to enter an open-label extension (OLE) lasting up to about 1 year. There is no placebo during the OLE, and all participants will receive the active study drug.
You are now leaving www.STEADY1.com and being redirected to a website that is not operated by Clinical Trial Media Inc.